On one hand, “suppressor” TIL subsets (e.g., FoxP3+, CD4+) can harbor immunosuppressive activity, promote tumor invasion and restrict the effectiveness of immunotherapeutic strategies [29,30]; on the other hand, “effector” TILs (e.g., CD3+, CD8+) have substantial anti-tumor and anti-proliferative capabilities, and have been found to be associated with improved pathological response and better clinical outcome [5,18,22,32,33,34,35,36,37,38]. The gene discussed is FOXP3; the disease is neoplasm.